In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Pharmaceutical company GlaxoSmithKline Limited (GSK) in Kenya has officially changed its legal entity name to Haleon Kenya ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Reading a pamphlet in the doctor’s office about which vaccines to get may help nudge older adults to get vaccinated.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

But the shingles studies published in 2024, along with a host of new papers, add weight to an alternative decades-old ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

The work on mRNA vaccines is especially important for bird flu. Most flu vaccines are currently made using a decades-old ...